menu
    • menu
    [{"orgOrder":0,"company":"Akome Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Akome Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akome Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Akome Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Abinopharm Inc","sponsor":"Prorelix Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Mononucleotide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 1; Nicotinamide\/nicotinic acid mononucleotide adenylyltransferase 3; DNA ligase","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Abinopharm Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abinopharm Inc \/ Prorelix Research","highestDevelopmentStatusID":"1","companyTruncated":"Abinopharm Inc \/ Prorelix Research"},{"orgOrder":0,"company":"Harbin Medical University","sponsor":"Yangtze River Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Harbin Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Harbin Medical University \/ Yangtze River Pharmaceutical Group","highestDevelopmentStatusID":"1","companyTruncated":"Harbin Medical University \/ Yangtze River Pharmaceutical Group"},{"orgOrder":0,"company":"Define Biotech","sponsor":"ABVC BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Agreement","leadProduct":"Beta Glucan","moa":"Beta-glucan receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Define Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Define Biotech \/ ABVC BioPharma","highestDevelopmentStatusID":"1","companyTruncated":"Define Biotech \/ ABVC BioPharma"},{"orgOrder":0,"company":"Loughborough University","sponsor":"Bridge Farm Nurseries Limited, Spalding, UK","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Loughborough University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loughborough University \/ Bridge Farm Nurseries Limited, Spalding, UK","highestDevelopmentStatusID":"1","companyTruncated":"Loughborough University \/ Bridge Farm Nurseries Limited, Spalding, UK"},{"orgOrder":0,"company":"Inha University","sponsor":"Terumo","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Nitrate","moa":"Carbonic anhydrase I (CA-I)","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Inha University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inha University \/ Terumo","highestDevelopmentStatusID":"1","companyTruncated":"Inha University \/ Terumo"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Samjin Pharmaceutical | Medtronic plc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Rivaroxaban","moa":"Coagulation factor X","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Seoul National University Hospital \/ Samjin Pharmaceutical | Medtronic plc","highestDevelopmentStatusID":"1","companyTruncated":"Seoul National University Hospital \/ Samjin Pharmaceutical | Medtronic plc"},{"orgOrder":0,"company":"Nicosia General Hospital","sponsor":"University of Cyprus | AVVA Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"Collagen (CO)","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Nicosia General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nicosia General Hospital \/ University of Cyprus | AVVA Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Nicosia General Hospital \/ University of Cyprus | AVVA Pharma"},{"orgOrder":0,"company":"University of Regina","sponsor":"Iovate Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Creatine","moa":"Creatine kinase M-type; Creatine kinase U-type, mitochondrial; Creatine kinase B-type; Creatine kinase S-type, mitochondrial; Sodium- and chloride-dependent creatine transporter 1; Guanidinoacetate N-methyltransferase","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"University of Regina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Regina \/ Iovate Health Sciences","highestDevelopmentStatusID":"1","companyTruncated":"University of Regina \/ Iovate Health Sciences"},{"orgOrder":0,"company":"Lepu Medical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Lepu Medical Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lepu Medical Technology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lepu Medical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"University of Toronto","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ University of Toronto","highestDevelopmentStatusID":"1","companyTruncated":"Unity Health Toronto \/ University of Toronto"},{"orgOrder":0,"company":"OtiTopic","sponsor":"Philip Morris International","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"OtiTopic","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"OtiTopic \/ Philip Morris International","highestDevelopmentStatusID":"1","companyTruncated":"OtiTopic \/ Philip Morris International"},{"orgOrder":0,"company":"Rhoshan Pharmaceuticals","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Rhoshan Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Rhoshan Pharmaceuticals \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Rhoshan Pharmaceuticals \/ Hyloris Pharmaceuticals"},{"orgOrder":0,"company":"University of Stirling","sponsor":"Danone Nutricia Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Fish Oil","moa":"Diacylglycerol O-acyltransferase 2; Prostaglandin G\/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"University of Stirling","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Stirling \/ Danone Nutricia Research","highestDevelopmentStatusID":"1","companyTruncated":"University of Stirling \/ Danone Nutricia Research"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Everolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Sinomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Sinomed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinomed \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sinomed \/ Undisclosed"},{"orgOrder":0,"company":"Jena University Hospital","sponsor":"Concept Medical | Vascuscience | CoreLab Black Forest | Center for Clinical Studies, Jena University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Jena University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jena University Hospital \/ Concept Medical | Vascuscience | CoreLab Black Forest | Center for Clinical Studies, Jena University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Jena University Hospital \/ Concept Medical | Vascuscience | CoreLab Black Forest | Center for Clinical Studies, Jena University Hospital"},{"orgOrder":0,"company":"Jena University Hospital","sponsor":"Concept Medical | Vascuscience | CoreLab Black Forest | Center for Clinical Studies, University Hospital Jena","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Jena University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jena University Hospital \/ Concept Medical | Vascuscience | CoreLab Black Forest | Center for Clinical Studies, University Hospital Jena","highestDevelopmentStatusID":"1","companyTruncated":"Jena University Hospital \/ Concept Medical | Vascuscience | CoreLab Black Forest | Center for Clinical Studies, University Hospital Jena"},{"orgOrder":0,"company":"MedAlliance","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"MedAlliance","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MedAlliance \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"MedAlliance \/ Undisclosed"},{"orgOrder":0,"company":"Surmodics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Surmodics \/ Undisclosed"},{"orgOrder":0,"company":"Surmodics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Surmodics \/ Undisclosed"},{"orgOrder":0,"company":"Surmodics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Surmodics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Surmodics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Surmodics \/ Undisclosed"},{"orgOrder":0,"company":"Orchestra Biomed","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Financing","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Orchestra Biomed","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.040000000000000001,"dosageForm":"Implant","sponsorNew":"Orchestra Biomed \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Orchestra Biomed \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Anesthesia Research Group UA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UKRAINE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Propofol","moa":"GABA-A receptor; anion channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Anesthesia Research Group UA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anesthesia Research Group UA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Anesthesia Research Group UA \/ Undisclosed"},{"orgOrder":0,"company":"Fraser Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Fraser Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fraser Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Fraser Health \/ Undisclosed"},{"orgOrder":0,"company":"Lo.Li.Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Inositol","moa":"HCAR3\/NIACR1","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Lo.Li.Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lo.Li.Pharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Lo.Li.Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Cereno Scientific","sponsor":"Worldwide Clinical Trials | Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CS1","moa":"HDAC","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Cereno Scientific","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Cereno Scientific \/ Worldwide Clinical Trials | Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Cereno Scientific \/ Worldwide Clinical Trials | Abbott Laboratories"},{"orgOrder":0,"company":"Aarhus University Hospital","sponsor":"HeartFlow","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rosuvastatin Calcium","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Aarhus University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aarhus University Hospital \/ HeartFlow","highestDevelopmentStatusID":"1","companyTruncated":"Aarhus University Hospital \/ HeartFlow"},{"orgOrder":0,"company":"23andMe","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Simvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"23andMe \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"23andMe \/ Undisclosed"},{"orgOrder":0,"company":"ADVANCED LIFE SOLUTIONS","sponsor":"Complexo Hospitalario Universitario de A Coru\u00f1a","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Polyethylene Glycol-35","moa":"Homeostasis","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"ADVANCED LIFE SOLUTIONS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"ADVANCED LIFE SOLUTIONS \/ Complexo Hospitalario Universitario de A Coru\u00f1a","highestDevelopmentStatusID":"1","companyTruncated":"ADVANCED LIFE SOLUTIONS \/ Complexo Hospitalario Universitario de A Coru\u00f1a"},{"orgOrder":0,"company":"Momentum Research Inc","sponsor":"Saint-Louis-Lariboisi\u00e8re University Hospitals | Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Ringer\\'S Solution","moa":"Homeostasis","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Momentum Research Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Momentum Research Inc \/ Saint-Louis-Lariboisi\u00e8re University Hospitals | Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Momentum Research Inc \/ Saint-Louis-Lariboisi\u00e8re University Hospitals | Abbott Laboratories"},{"orgOrder":0,"company":"Moon (Guangzhou) Biotechnology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Moon (Guangzhou) Biotechnology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moon (Guangzhou) Biotechnology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Moon (Guangzhou) Biotechnology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Glac Biotech Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Glac Biotech Co., Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glac Biotech Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Glac Biotech Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"NKGen Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Troculeucel","moa":"KIRS","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"NKGen Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NKGen Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NKGen Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"Hope Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"HB-adMSC","moa":"Mesenchymal stem cells","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hope Biosciences \/ Hope Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Hope Biosciences \/ Hope Biosciences"},{"orgOrder":0,"company":"Kaneka Nutrients","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Kaneka Nutrients","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kaneka Nutrients \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Kaneka Nutrients \/ Undisclosed"},{"orgOrder":0,"company":"Montreal Heart Institute","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sacubitril Sodium","moa":"Neprilysin","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Montreal Heart Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Montreal Heart Institute \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Montreal Heart Institute \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ezetimibe","moa":"Niemann-Pick C1-like protein 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Seoul National University Hospital \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"MicroPort CRM","sponsor":"Gateway Institute for Brain Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Dual Antiplatelet Therapy","moa":"P2Y12 receptor \/ COX-1","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"MicroPort CRM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MicroPort CRM \/ Gateway Institute for Brain Research","highestDevelopmentStatusID":"1","companyTruncated":"MicroPort CRM \/ Gateway Institute for Brain Research"},{"orgOrder":0,"company":"S.LAB (SOLOWAYS)","sponsor":"Center of New Medical Technologies | Triangel Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor alpha; Sterol regulatory element-binding protein 1","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"S.LAB (SOLOWAYS)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"S.LAB (SOLOWAYS) \/ Center of New Medical Technologies | Triangel Scientific","highestDevelopmentStatusID":"1","companyTruncated":"S.LAB (SOLOWAYS) \/ Center of New Medical Technologies | Triangel Scientific"},{"orgOrder":0,"company":"National Research Council, Spain","sponsor":"Beps Holding GmbH | Olivenova Health Sl","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"Prostaglandin G\/H synthase 2|Prostaglandin G\/H synthase 1|Peroxisome proliferator-activated receptor gamma|Peroxisome proliferator-activated receptor delta|Free fatty acid receptor 1|Sodium\/calcium exchanger 1|Fatty acid-binding protein, brain; Acyl-CoA (","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"National Research Council, Spain","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Research Council, Spain \/ Beps Holding GmbH | Olivenova Health Sl","highestDevelopmentStatusID":"1","companyTruncated":"National Research Council, Spain \/ Beps Holding GmbH | Olivenova Health Sl"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Dalhousie University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Protein","moa":"Protein","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova Scotia Health Authority \/ Dalhousie University","highestDevelopmentStatusID":"1","companyTruncated":"Nova Scotia Health Authority \/ Dalhousie University"},{"orgOrder":0,"company":"Meditrix","sponsor":"Fujita Health University | Boston Scientific | National University of Ireland, Galway","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Prasugrel","moa":"Purinergic receptor P2Y12","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Meditrix","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Meditrix \/ Fujita Health University | Boston Scientific | National University of Ireland, Galway","highestDevelopmentStatusID":"1","companyTruncated":"Meditrix \/ Fujita Health University | Boston Scientific | National University of Ireland, Galway"},{"orgOrder":0,"company":"University of Ulster","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"University of Ulster","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Ulster \/ Royal DSM","highestDevelopmentStatusID":"1","companyTruncated":"University of Ulster \/ Royal DSM"},{"orgOrder":0,"company":"University of Edinburgh","sponsor":"AstraZeneca | NHS Lothian","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"University of Edinburgh","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Edinburgh \/ AstraZeneca | NHS Lothian","highestDevelopmentStatusID":"1","companyTruncated":"University of Edinburgh \/ AstraZeneca | NHS Lothian"},{"orgOrder":0,"company":"Sequana Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Sequana Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sequana Medical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Sequana Medical \/ Undisclosed"},{"orgOrder":0,"company":"China National Center for Cardiovascular Diseases","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Tafolecimab","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"China National Center for Cardiovascular Diseases","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"China National Center for Cardiovascular Diseases \/ Innovent Biologics","highestDevelopmentStatusID":"1","companyTruncated":"China National Center for Cardiovascular Diseases \/ Innovent Biologics"},{"orgOrder":0,"company":"PharmAbcine","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"PMC-403","moa":"Tie2","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"PharmAbcine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmAbcine \/ National Institutes of Health","highestDevelopmentStatusID":"1","companyTruncated":"PharmAbcine \/ National Institutes of Health"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Patisiran","moa":"Transthyretin mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Alnylam Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Scilex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Scilex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vedic Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Dolichos Biflorus Seed Extract","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Vedic Lifesciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vedic Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Vedic Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"Universitat de Lleida","sponsor":"Pharmactive Biotech Products S.L","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SPAIN","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Abg+ Black Garlin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Universitat de Lleida","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Universitat de Lleida \/ Pharmactive Biotech Products S.L","highestDevelopmentStatusID":"1","companyTruncated":"Universitat de Lleida \/ Pharmactive Biotech Products S.L"},{"orgOrder":0,"company":"AB Biotics","sponsor":"University of Extremadura","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SPAIN","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Ab-Life with Monacolin K","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"AB Biotics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AB Biotics \/ University of Extremadura","highestDevelopmentStatusID":"1","companyTruncated":"AB Biotics \/ University of Extremadura"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Akk Formula Prebiotic","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Industrial Farmac\u00e9utica Cantabria","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SPAIN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AM3","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Industrial Farmac\u00e9utica Cantabria","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Industrial Farmac\u00e9utica Cantabria \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Industrial Farmac\u00e9utica Cantabria \/ Undisclosed"},{"orgOrder":0,"company":"SunWay Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Ankascin 568-P Red Yeast Rice","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"SunWay Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SunWay Biotech \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"SunWay Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Analyze & Realize","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Arterin Cholesterol","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Perrigo Company plc \/ Analyze & Realize","highestDevelopmentStatusID":"1","companyTruncated":"Perrigo Company plc \/ Analyze & Realize"},{"orgOrder":0,"company":"Peijia Medical","sponsor":"General Hospital of Shenyang Military Region | Shanghai Zhongshan Hospital | Guangdong Provincial People's Hospital | The Second Affiliated Hospital of Harbin Medical University | Air Force Military Medical University, China | West China Hospital | Beijin","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Artificial Aortic Valve","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Peijia Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peijia Medical \/ General Hospital of Shenyang Military Region | Shanghai Zhongshan Hospital | Guangdong Provincial People's Hospital | The Second Affiliated Hospital of Harbin Medical University | Air Force Military Medical University, China | West China Hospital | Beijin","highestDevelopmentStatusID":"1","companyTruncated":"Peijia Medical \/ General Hospital of Shenyang Military Region | Shanghai Zhongshan Hospital | Guangdong Provincial People's Hospital | The Second Affiliated Hospital of Harbin Medical University | Air Force Military Medical University, China | West China Hospital | Beijin"},{"orgOrder":0,"company":"Helse Stavanger","sponsor":"Evonik","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Availom","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Helse Stavanger","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Helse Stavanger \/ Evonik","highestDevelopmentStatusID":"1","companyTruncated":"Helse Stavanger \/ Evonik"},{"orgOrder":0,"company":"BIO-CAT","sponsor":"Biofortis Clinical Research, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Bacillus Subtilis BS50 spore","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"BIO-CAT","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BIO-CAT \/ Biofortis Clinical Research, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"BIO-CAT \/ Biofortis Clinical Research, Inc."},{"orgOrder":0,"company":"King's College London","sponsor":"VDF FutureCeuticals Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Betalains","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"King's College London","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"King's College London \/ VDF FutureCeuticals Inc.","highestDevelopmentStatusID":"1","companyTruncated":"King's College London \/ VDF FutureCeuticals Inc."},{"orgOrder":0,"company":"Loughborough University","sponsor":"Volac International Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Bioactive Whey Protein Concentrate","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Loughborough University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Loughborough University \/ Volac International Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Loughborough University \/ Volac International Ltd"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Buckwheat Husk Extract","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Sachet","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Hygieia Biotech","sponsor":"Zhejiang Chinese Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Calcium-a-ketoglutarate","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Shenzhen Hygieia Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen Hygieia Biotech \/ Zhejiang Chinese Medical University","highestDevelopmentStatusID":"1","companyTruncated":"Shenzhen Hygieia Biotech \/ Zhejiang Chinese Medical University"},{"orgOrder":0,"company":"Tongji Hospital","sponsor":"Jianmin Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Calculus Bovis Sativus","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Tongji Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tongji Hospital \/ Jianmin Pharmaceutical Group","highestDevelopmentStatusID":"1","companyTruncated":"Tongji Hospital \/ Jianmin Pharmaceutical Group"},{"orgOrder":0,"company":"BIO-CAT","sponsor":"Atlantia Food Clinical Trials | Cork University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Candida Cylindracea Lipase","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"BIO-CAT","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BIO-CAT \/ Atlantia Food Clinical Trials | Cork University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"BIO-CAT \/ Atlantia Food Clinical Trials | Cork University Hospital"},{"orgOrder":0,"company":"Ncardia","sponsor":"BlueRock Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Cell & Gene Therapy","year":"2020","type":"Collaboration","leadProduct":"Cardiomyocytes","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Ncardia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ncardia \/ BlueRock Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Ncardia \/ BlueRock Therapeutics"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Choleswise","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Columbia University","sponsor":"Brigham and Women's Hospital | Fred Hutchinson Cancer Center | Mars","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Cocoa Extract","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Brigham and Women's Hospital | Fred Hutchinson Cancer Center | Mars","highestDevelopmentStatusID":"1","companyTruncated":"Columbia University \/ Brigham and Women's Hospital | Fred Hutchinson Cancer Center | Mars"},{"orgOrder":0,"company":"University of Georgia","sponsor":"National Cottonseed Products Association | Cotton Incorporated | University of Georgia Obesity Initiative","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Cottonseed Oil","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"University of Georgia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oil","sponsorNew":"University of Georgia \/ National Cottonseed Products Association | Cotton Incorporated | University of Georgia Obesity Initiative","highestDevelopmentStatusID":"1","companyTruncated":"University of Georgia \/ National Cottonseed Products Association | Cotton Incorporated | University of Georgia Obesity Initiative"},{"orgOrder":0,"company":"Greenyn Biotechnology","sponsor":"Chia Nan University of Pharmacy and Science","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Crassocephalum Rabens Extract","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Greenyn Biotechnology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Greenyn Biotechnology \/ Chia Nan University of Pharmacy and Science","highestDevelopmentStatusID":"1","companyTruncated":"Greenyn Biotechnology \/ Chia Nan University of Pharmacy and Science"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Siemens Medical Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CT-MPI","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gabrail Cancer Center Research \/ Siemens Medical Solutions","highestDevelopmentStatusID":"1","companyTruncated":"Gabrail Cancer Center Research \/ Siemens Medical Solutions"},{"orgOrder":0,"company":"University of Aarhus","sponsor":"Danish Diabetes Academy | AP Moeller Foundation | Aarhus University Hospital | Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"D-\u0392eta-Hydroxybutyrate","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"University of Aarhus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Aarhus \/ Danish Diabetes Academy | AP Moeller Foundation | Aarhus University Hospital | Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"University of Aarhus \/ Danish Diabetes Academy | AP Moeller Foundation | Aarhus University Hospital | Novo Nordisk"},{"orgOrder":0,"company":"Columbia University","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Ensure Surgery Immunonutrition","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Columbia University \/ Abbott Laboratories"},{"orgOrder":0,"company":"Pluristyx","sponsor":"AgeX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Agreement","leadProduct":"ESI Human Embryonic Stem Cell","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Pluristyx","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pluristyx \/ AgeX Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Pluristyx \/ AgeX Therapeutics"},{"orgOrder":0,"company":"Universit\u00e9 de Sherbrooke","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Exogenous Ketone Salt","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Universit\u00e9 de Sherbrooke","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universit\u00e9 de Sherbrooke \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"1","companyTruncated":"Universit\u00e9 de Sherbrooke \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Fundaci\u00f3 Eurecat","sponsor":"University Rovira i Virgili | Grandes Vinos y Vi\u00f1edos S.A.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Extract from the Wine Industry","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Fundaci\u00f3 Eurecat","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundaci\u00f3 Eurecat \/ University Rovira i Virgili | Grandes Vinos y Vi\u00f1edos S.A.","highestDevelopmentStatusID":"1","companyTruncated":"Fundaci\u00f3 Eurecat \/ University Rovira i Virgili | Grandes Vinos y Vi\u00f1edos S.A."},{"orgOrder":0,"company":"ESI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Food Supplement","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"ESI","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ESI \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"ESI \/ Undisclosed"},{"orgOrder":0,"company":"Amazentis","sponsor":"SGS proderm GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Food Supplement","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Amazentis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Amazentis \/ SGS proderm GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Amazentis \/ SGS proderm GmbH"},{"orgOrder":0,"company":"DOMCA S.A.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Garlic","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"DOMCA S.A.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DOMCA S.A. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"DOMCA S.A. \/ Undisclosed"},{"orgOrder":0,"company":"The Perfect Series Sdn Bhd","sponsor":"UCSI University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Ginger extract","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"The Perfect Series Sdn Bhd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Perfect Series Sdn Bhd \/ UCSI University","highestDevelopmentStatusID":"1","companyTruncated":"The Perfect Series Sdn Bhd \/ UCSI University"},{"orgOrder":0,"company":"Indena","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ITALY","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Grape Seed Extract","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Indena","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indena \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Indena \/ Undisclosed"},{"orgOrder":0,"company":"Taipei Medical University","sponsor":"Eagletek Corp.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Green Tea Extract","moa":"Muscarinic acetylcholine receptor M2 (CHRM2)","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Taipei Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taipei Medical University \/ Eagletek Corp.","highestDevelopmentStatusID":"1","companyTruncated":"Taipei Medical University \/ Eagletek Corp."},{"orgOrder":0,"company":"AMOREPACIFIC CORPORATION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Heukcha Extract","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"AMOREPACIFIC CORPORATION","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMOREPACIFIC CORPORATION \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AMOREPACIFIC CORPORATION \/ Undisclosed"},{"orgOrder":0,"company":"Oxford Brookes University","sponsor":"Suntory Beverage & Food Limited","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"High Potassium Water","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Oxford Brookes University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Brookes University \/ Suntory Beverage & Food Limited","highestDevelopmentStatusID":"1","companyTruncated":"Oxford Brookes University \/ Suntory Beverage & Food Limited"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Analyze & Realize","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Humiome Post LB","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Analyze & Realize","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Analyze & Realize"},{"orgOrder":0,"company":"Medinutra LLC","sponsor":"Dairy Management Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Hydrolyzed Whey","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Medinutra LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medinutra LLC \/ Dairy Management Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Medinutra LLC \/ Dairy Management Inc."},{"orgOrder":0,"company":"National Hellenic Research Foundation","sponsor":"Theracell Advanced Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GREECE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Hydroxypropyl Methyl Cellulose","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"National Hellenic Research Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Hellenic Research Foundation \/ Theracell Advanced Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"National Hellenic Research Foundation \/ Theracell Advanced Biotechnology"},{"orgOrder":0,"company":"Octapharma","sponsor":"Norton Heart & Vascular Institute In Louisvill","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Collaboration","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Octapharma \/ Norton Heart & Vascular Institute In Louisvill","highestDevelopmentStatusID":"1","companyTruncated":"Octapharma \/ Norton Heart & Vascular Institute In Louisvill"},{"orgOrder":0,"company":"Amsterdam UMC, VUmc","sponsor":"Abiomed Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Impella 5.5","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Amsterdam UMC, VUmc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amsterdam UMC, VUmc \/ Abiomed Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Amsterdam UMC, VUmc \/ Abiomed Inc."},{"orgOrder":0,"company":"Korea Ginseng Corporation","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Korean Red Ginseng Extract","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Korea Ginseng Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korea Ginseng Corporation \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"Korea Ginseng Corporation \/ Nutrasource"},{"orgOrder":0,"company":"Lescuyer Laboratory","sponsor":"Hopital Gabriel Montpied | Centre de Recherche en Nutrition Humaine d'Auvergne | Clinique M\u00e9dicale Cardio-Pneumologie de Durtol | Universit\u00e9 d'Auvergne","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Limicol","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Lescuyer Laboratory","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lescuyer Laboratory \/ Hopital Gabriel Montpied | Centre de Recherche en Nutrition Humaine d'Auvergne | Clinique M\u00e9dicale Cardio-Pneumologie de Durtol | Universit\u00e9 d'Auvergne","highestDevelopmentStatusID":"1","companyTruncated":"Lescuyer Laboratory \/ Hopital Gabriel Montpied | Centre de Recherche en Nutrition Humaine d'Auvergne | Clinique M\u00e9dicale Cardio-Pneumologie de Durtol | Universit\u00e9 d'Auvergne"},{"orgOrder":0,"company":"LL Prosper Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"LLP-01","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"LL Prosper Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LL Prosper Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"LL Prosper Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Prenetics Global","sponsor":"San Francisco Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"HONG KONG","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Longevity Pill","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Prenetics Global","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pill","sponsorNew":"Prenetics Global \/ San Francisco Research Institute","highestDevelopmentStatusID":"1","companyTruncated":"Prenetics Global \/ San Francisco Research Institute"},{"orgOrder":0,"company":"Clinical Nutrition Research Center, Illinois Institute of Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MegaNatural-BP","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Clinical Nutrition Research Center, Illinois Institute of Technology","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinical Nutrition Research Center, Illinois Institute of Technology \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Clinical Nutrition Research Center, Illinois Institute of Technology \/ Undisclosed"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Melagene Drink","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Discovery Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"miRNA-125b","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Horizon Discovery Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Horizon Discovery Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Horizon Discovery Group \/ Undisclosed"},{"orgOrder":0,"company":"Amazentis","sponsor":"Radicle Science","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Mitopure Urolithin A","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Amazentis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amazentis \/ Radicle Science","highestDevelopmentStatusID":"1","companyTruncated":"Amazentis \/ Radicle Science"},{"orgOrder":0,"company":"Sofia Pavanello","sponsor":"Mibelle AG","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Monarda Didyma Extract","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Sofia Pavanello","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sofia Pavanello \/ Mibelle AG","highestDevelopmentStatusID":"1","companyTruncated":"Sofia Pavanello \/ Mibelle AG"},{"orgOrder":0,"company":"Myota Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Probiotic","year":"2024","type":"Inapplicable","leadProduct":"Myota\\'S Prebiotic Fibre Blend","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Myota Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Myota Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Myota Health \/ Undisclosed"},{"orgOrder":0,"company":"The Center for Applied Health Sciences, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Nad3","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"The Center for Applied Health Sciences, LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Center for Applied Health Sciences, LLC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"The Center for Applied Health Sciences, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Amway (China) R&D Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Nutrilite Protein MetX Pro","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Amway (China) R&D Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amway (China) R&D Center \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Amway (China) R&D Center \/ Undisclosed"},{"orgOrder":0,"company":"Barts & The London NHS Trust","sponsor":"Queen Mary University of London | Nutricia Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Nutritional Supplement","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Barts & The London NHS Trust","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Barts & The London NHS Trust \/ Queen Mary University of London | Nutricia Inc","highestDevelopmentStatusID":"1","companyTruncated":"Barts & The London NHS Trust \/ Queen Mary University of London | Nutricia Inc"},{"orgOrder":0,"company":"Les Derives Resiniques et Terpeniques","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Oligopin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Les Derives Resiniques et Terpeniques","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Les Derives Resiniques et Terpeniques \/ KGK Science","highestDevelopmentStatusID":"1","companyTruncated":"Les Derives Resiniques et Terpeniques \/ KGK Science"},{"orgOrder":0,"company":"Santa Maria de la Salud, Argentina","sponsor":"Gador S.A.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ARGENTINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Omega-3 Ethyl Esters","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Santa Maria de la Salud, Argentina","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Santa Maria de la Salud, Argentina \/ Gador S.A.","highestDevelopmentStatusID":"1","companyTruncated":"Santa Maria de la Salud, Argentina \/ Gador S.A."},{"orgOrder":0,"company":"Ekrem Bilal Karaayvaz","sponsor":"Medicana","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ozone","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Ekrem Bilal Karaayvaz","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ekrem Bilal Karaayvaz \/ Medicana","highestDevelopmentStatusID":"1","companyTruncated":"Ekrem Bilal Karaayvaz \/ Medicana"},{"orgOrder":0,"company":"Institut Pertanian Bogor","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDONESIA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Palm Oil Enriched With Plant Sterols","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Institut Pertanian Bogor","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oil","sponsorNew":"Institut Pertanian Bogor \/ BASF","highestDevelopmentStatusID":"1","companyTruncated":"Institut Pertanian Bogor \/ BASF"},{"orgOrder":0,"company":"A-Mansia Biotech S.A.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"LUXEMBOURG","productType":"Probiotic","year":"2021","type":"Inapplicable","leadProduct":"Pasteurized A. Muciniphila","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"A-Mansia Biotech S.A.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"A-Mansia Biotech S.A. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"A-Mansia Biotech S.A. \/ Undisclosed"},{"orgOrder":0,"company":"Centro de Edafolog\u00eda y Biolog\u00eda Aplicada del Segura","sponsor":"Universidad Cat\u00f3lica San Antonio de Murcia","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SPAIN","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Plant Based Extract Rich In Phytosterols, Phytostanols, Resveratrol & Hydroxytyrosol","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Centro de Edafolog\u00eda y Biolog\u00eda Aplicada del Segura","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centro de Edafolog\u00eda y Biolog\u00eda Aplicada del Segura \/ Universidad Cat\u00f3lica San Antonio de Murcia","highestDevelopmentStatusID":"1","companyTruncated":"Centro de Edafolog\u00eda y Biolog\u00eda Aplicada del Segura \/ Universidad Cat\u00f3lica San Antonio de Murcia"},{"orgOrder":0,"company":"Brightseed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Plant Derived Phenolics","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Brightseed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brightseed \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Brightseed \/ Undisclosed"},{"orgOrder":0,"company":"Chongqing Traditional Chinese Medicine Hospital","sponsor":"Chongqing Science and Technology Commission | Chongqing Health and Family Planning Commission","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Pogejiuxin Decoction","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Chongqing Traditional Chinese Medicine Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Chongqing Traditional Chinese Medicine Hospital \/ Chongqing Science and Technology Commission | Chongqing Health and Family Planning Commission","highestDevelopmentStatusID":"1","companyTruncated":"Chongqing Traditional Chinese Medicine Hospital \/ Chongqing Science and Technology Commission | Chongqing Health and Family Planning Commission"},{"orgOrder":0,"company":"University of Ulster","sponsor":"University of Parma | Activ'inside","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Polyphenol Extract","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"University of Ulster","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Ulster \/ University of Parma | Activ'inside","highestDevelopmentStatusID":"1","companyTruncated":"University of Ulster \/ University of Parma | Activ'inside"},{"orgOrder":0,"company":"Nature's Sunshine Products, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Power Line Program","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Nature's Sunshine Products, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nature's Sunshine Products, Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nature's Sunshine Products, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Thorne HealthTech","sponsor":"Indena","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Quercetin Phytosome","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Thorne HealthTech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Thorne HealthTech \/ Indena","highestDevelopmentStatusID":"1","companyTruncated":"Thorne HealthTech \/ Indena"},{"orgOrder":0,"company":"Bioenergy Life Science, Inc.","sponsor":"KGK Science | University of Washington","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Riagev","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Bioenergy Life Science, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioenergy Life Science, Inc. \/ KGK Science | University of Washington","highestDevelopmentStatusID":"1","companyTruncated":"Bioenergy Life Science, Inc. \/ KGK Science | University of Washington"},{"orgOrder":0,"company":"Kansas State University","sponsor":"MGP Ingredients, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"RS4 bar","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Kansas State University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kansas State University \/ MGP Ingredients, Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Kansas State University \/ MGP Ingredients, Inc."},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Salvia Haenkei","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IBSA Institut Biochimique \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"IBSA Institut Biochimique \/ Undisclosed"},{"orgOrder":0,"company":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz","sponsor":"AlgaEnergy, S.A.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Spirulina","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz \/ AlgaEnergy, S.A.","highestDevelopmentStatusID":"1","companyTruncated":"Instituto de Investigaci\u00f3n Hospital Universitario La Paz \/ AlgaEnergy, S.A."},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"National Research Agency, France | The Company SOLUTEXGC, S.L","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"SPM-enriched Marine Oil","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oil","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ National Research Agency, France | The Company SOLUTEXGC, S.L","highestDevelopmentStatusID":"1","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ National Research Agency, France | The Company SOLUTEXGC, S.L"},{"orgOrder":0,"company":"Swisse Wellness Pty Ltd","sponsor":"Commonwealth Scientific & Industrial Research Organisation | Bionap SRL","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Swisse Nutra","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Swisse Wellness Pty Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swisse Wellness Pty Ltd \/ Commonwealth Scientific & Industrial Research Organisation | Bionap SRL","highestDevelopmentStatusID":"1","companyTruncated":"Swisse Wellness Pty Ltd \/ Commonwealth Scientific & Industrial Research Organisation | Bionap SRL"},{"orgOrder":0,"company":"KU Leuven","sponsor":"Mildmay Uganda","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Tamarindus Indica Fruit Juice","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"KU Leuven","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KU Leuven \/ Mildmay Uganda","highestDevelopmentStatusID":"1","companyTruncated":"KU Leuven \/ Mildmay Uganda"},{"orgOrder":0,"company":"SolasCure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Tarumase","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"SolasCure","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"SolasCure \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"SolasCure \/ Undisclosed"},{"orgOrder":0,"company":"TCI Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"TCI904","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"TCI Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCI Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"TCI Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Bispebjerg Hospital","sponsor":"Independent Research Fund Denmark | Hartmann Fonden | University Hospital Bispebjerg and Frederiksberg","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Thoracentesis","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Bispebjerg Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bispebjerg Hospital \/ Independent Research Fund Denmark | Hartmann Fonden | University Hospital Bispebjerg and Frederiksberg","highestDevelopmentStatusID":"1","companyTruncated":"Bispebjerg Hospital \/ Independent Research Fund Denmark | Hartmann Fonden | University Hospital Bispebjerg and Frederiksberg"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Biofortis M\u00e9rieux Nutriscience","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Totum-070","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Biofortis M\u00e9rieux Nutriscience","highestDevelopmentStatusID":"1","companyTruncated":"Valbiotis \/ Biofortis M\u00e9rieux Nutriscience"},{"orgOrder":0,"company":"Valbiotis","sponsor":"University Hospital, Clermont-Ferrand","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Totum-070","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ University Hospital, Clermont-Ferrand","highestDevelopmentStatusID":"1","companyTruncated":"Valbiotis \/ University Hospital, Clermont-Ferrand"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Totum-070","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Valbiotis \/ Undisclosed"},{"orgOrder":0,"company":"Valbiotis","sponsor":"BioTeSys GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Totum-854","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ BioTeSys GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Valbiotis \/ BioTeSys GmbH"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Excelya","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Totum-854","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Valbiotis \/ Excelya","highestDevelopmentStatusID":"1","companyTruncated":"Valbiotis \/ Excelya"},{"orgOrder":0,"company":"OMNIFARMA LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Trans-Resveratrol Extract","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"OMNIFARMA LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OMNIFARMA LLC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"OMNIFARMA LLC \/ Undisclosed"},{"orgOrder":0,"company":"BrosMed Medical","sponsor":"CCRF Inc., Beijing, China","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Tri-Wire Peripheral Balloon Dilatation Catheter","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"BrosMed Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BrosMed Medical \/ CCRF Inc., Beijing, China","highestDevelopmentStatusID":"1","companyTruncated":"BrosMed Medical \/ CCRF Inc., Beijing, China"},{"orgOrder":0,"company":"Calroy Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Vascanox Hp","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Calroy Health Sciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Calroy Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Calroy Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Alucent Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Vessel Restoration System","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Alucent Biomedical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Alucent Biomedical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Alucent Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Viome","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"VIOME","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Viome","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viome \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Viome \/ Undisclosed"},{"orgOrder":0,"company":"Universiti Sains Malaysia","sponsor":"Gold Choice Food Industries Sdn. Bhd","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"MALAYSIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Vitamin E Incorporated Oat Supplement","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Universiti Sains Malaysia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universiti Sains Malaysia \/ Gold Choice Food Industries Sdn. Bhd","highestDevelopmentStatusID":"1","companyTruncated":"Universiti Sains Malaysia \/ Gold Choice Food Industries Sdn. Bhd"},{"orgOrder":0,"company":"LivaNova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Vitaria","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"LivaNova","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LivaNova \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"LivaNova \/ Undisclosed"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Maastricht University Medical Center | Wageningen University and Research | FrieslandCampina | ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Voila","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Leiden University Medical Center \/ Maastricht University Medical Center | Wageningen University and Research | FrieslandCampina | ZonMw","highestDevelopmentStatusID":"1","companyTruncated":"Leiden University Medical Center \/ Maastricht University Medical Center | Wageningen University and Research | FrieslandCampina | ZonMw"},{"orgOrder":0,"company":"Chinese Pulmonary Vascular Disease Research Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tolvaptan","moa":"Vasopressin V2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Chinese Pulmonary Vascular Disease Research Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese Pulmonary Vascular Disease Research Group \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Chinese Pulmonary Vascular Disease Research Group \/ Undisclosed"},{"orgOrder":0,"company":"Gia Dinh People Hospital","sponsor":"Otsuka Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"VIETNAM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tolvaptan","moa":"Vasopressin V2 receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Gia Dinh People Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gia Dinh People Hospital \/ Otsuka Holdings","highestDevelopmentStatusID":"1","companyTruncated":"Gia Dinh People Hospital \/ Otsuka Holdings"},{"orgOrder":0,"company":"Closed Loop Medicine","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"Amlodipine","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Closed Loop Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Closed Loop Medicine \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"1","companyTruncated":"Closed Loop Medicine \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"University of Alberta","sponsor":"Alberta Health services","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Amlodipine","moa":"Voltage-gated L-type calcium channel","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"University of Alberta","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alberta \/ Alberta Health services","highestDevelopmentStatusID":"1","companyTruncated":"University of Alberta \/ Alberta Health services"},{"orgOrder":0,"company":"Verve Medical","sponsor":"RQM+ | Dabl Ltd | Medical Labs Memphis - MLM","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Verve Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verve Medical \/ RQM+ | Dabl Ltd | Medical Labs Memphis - MLM","highestDevelopmentStatusID":"1","companyTruncated":"Verve Medical \/ RQM+ | Dabl Ltd | Medical Labs Memphis - MLM"},{"orgOrder":0,"company":"Beijing Anzhen Hospital","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Beijing Anzhen Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Catheter","sponsorNew":"Beijing Anzhen Hospital \/ Abbott Laboratories","highestDevelopmentStatusID":"1","companyTruncated":"Beijing Anzhen Hospital \/ Abbott Laboratories"},{"orgOrder":0,"company":"First Affiliated Hospital of Wannan Medical College","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"First Affiliated Hospital of Wannan Medical College","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"First Affiliated Hospital of Wannan Medical College \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"First Affiliated Hospital of Wannan Medical College \/ Undisclosed"},{"orgOrder":0,"company":"First Affiliated Hospital of Wannan Medical College","sponsor":"The First Affiliated Hospital of Anhui Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"First Affiliated Hospital of Wannan Medical College","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"First Affiliated Hospital of Wannan Medical College \/ The First Affiliated Hospital of Anhui Medical University","highestDevelopmentStatusID":"1","companyTruncated":"First Affiliated Hospital of Wannan Medical College \/ The First Affiliated Hospital of Anhui Medical University"},{"orgOrder":0,"company":"Harbin Medical University","sponsor":"Shanghai Shenqi Medical Technology Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Harbin Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harbin Medical University \/ Shanghai Shenqi Medical Technology Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Harbin Medical University \/ Shanghai Shenqi Medical Technology Co., Ltd"},{"orgOrder":0,"company":"Harbin Medical University","sponsor":"Shanghai Shenqi Medical Technology Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Harbin Medical University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harbin Medical University \/ Shanghai Shenqi Medical Technology Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Harbin Medical University \/ Shanghai Shenqi Medical Technology Co., Ltd"},{"orgOrder":0,"company":"Reliance Life Sciences Private Limited","sponsor":"Medicure","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Reliance Life Sciences Private Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reliance Life Sciences Private Limited \/ Medicure","highestDevelopmentStatusID":"1","companyTruncated":"Reliance Life Sciences Private Limited \/ Medicure"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Inserm UMR1087, CNRS UMR6291 | Clinique des Donn\u00e9es, CIC 1413, CHU Nantes | CIC-FEA, CIC 1413, CHU Nantes","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nantes University Hospital \/ Inserm UMR1087, CNRS UMR6291 | Clinique des Donn\u00e9es, CIC 1413, CHU Nantes | CIC-FEA, CIC 1413, CHU Nantes","highestDevelopmentStatusID":"1","companyTruncated":"Nantes University Hospital \/ Inserm UMR1087, CNRS UMR6291 | Clinique des Donn\u00e9es, CIC 1413, CHU Nantes | CIC-FEA, CIC 1413, CHU Nantes"},{"orgOrder":0,"company":"GCS Ramsay Sant\u00e9","sponsor":"Vivactis M2Research","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"GCS Ramsay Sant\u00e9","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GCS Ramsay Sant\u00e9 \/ Vivactis M2Research","highestDevelopmentStatusID":"1","companyTruncated":"GCS Ramsay Sant\u00e9 \/ Vivactis M2Research"},{"orgOrder":0,"company":"Amsterdam UMC, VUmc","sponsor":"Reinier de Graaf Groep | Janssen-Cilag","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Amsterdam UMC, VUmc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amsterdam UMC, VUmc \/ Reinier de Graaf Groep | Janssen-Cilag","highestDevelopmentStatusID":"1","companyTruncated":"Amsterdam UMC, VUmc \/ Reinier de Graaf Groep | Janssen-Cilag"},{"orgOrder":0,"company":"AronPharma Sp. z o. o.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"POLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"AronPharma Sp. z o. o.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AronPharma Sp. z o. o. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"AronPharma Sp. z o. o. \/ Undisclosed"},{"orgOrder":0,"company":"Universitat de Lleida","sponsor":"Pharmactive Biotech Products S.L","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SPAIN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Universitat de Lleida","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universitat de Lleida \/ Pharmactive Biotech Products S.L","highestDevelopmentStatusID":"1","companyTruncated":"Universitat de Lleida \/ Pharmactive Biotech Products S.L"},{"orgOrder":0,"company":"Leipzig Heart Science","sponsor":"Heart Center Leipzig at University of Leipzig | Helios Health Institute GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Leipzig Heart Science","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leipzig Heart Science \/ Heart Center Leipzig at University of Leipzig | Helios Health Institute GmbH","highestDevelopmentStatusID":"1","companyTruncated":"Leipzig Heart Science \/ Heart Center Leipzig at University of Leipzig | Helios Health Institute GmbH"},{"orgOrder":0,"company":"Berlin Heals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Berlin Heals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Berlin Heals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Berlin Heals \/ Undisclosed"},{"orgOrder":0,"company":"P+F Products","sponsor":"Meditrial","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"P+F Products","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"P+F Products \/ Meditrial","highestDevelopmentStatusID":"1","companyTruncated":"P+F Products \/ Meditrial"},{"orgOrder":0,"company":"IBSA Institut Biochimique","sponsor":"Informapro Srl","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"IBSA Institut Biochimique","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IBSA Institut Biochimique \/ Informapro Srl","highestDevelopmentStatusID":"1","companyTruncated":"IBSA Institut Biochimique \/ Informapro Srl"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Lipigon","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Secarna Pharma \/ Lipigon","highestDevelopmentStatusID":"1","companyTruncated":"Secarna Pharma \/ Lipigon"},{"orgOrder":0,"company":"Selah Therapeutics","sponsor":"Juvenescence","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Selah Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Selah Therapeutics \/ Juvenescence","highestDevelopmentStatusID":"1","companyTruncated":"Selah Therapeutics \/ Juvenescence"},{"orgOrder":0,"company":"Penumbra Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Penumbra Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Penumbra Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Penumbra Inc. \/ Undisclosed"},{"orgOrder":0,"company":"MyOme","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"MyOme","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MyOme \/ University of Pennsylvania","highestDevelopmentStatusID":"1","companyTruncated":"MyOme \/ University of Pennsylvania"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Ottawa Heart Institute Research Corporation | Medtronic plc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ Ottawa Heart Institute Research Corporation | Medtronic plc","highestDevelopmentStatusID":"1","companyTruncated":"University of British Columbia \/ Ottawa Heart Institute Research Corporation | Medtronic plc"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"American Heart Association | Apple Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ American Heart Association | Apple Inc.","highestDevelopmentStatusID":"1","companyTruncated":"Johns Hopkins University \/ American Heart Association | Apple Inc."},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"PhRMA Foundation | Apple Inc. | Itamar Medical","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ PhRMA Foundation | Apple Inc. | Itamar Medical","highestDevelopmentStatusID":"1","companyTruncated":"Johns Hopkins University \/ PhRMA Foundation | Apple Inc. | Itamar Medical"},{"orgOrder":0,"company":"Nationwide Children\u2019s Hospital","sponsor":"National Institutes of Health | Abbott Laboratories | The University of Pittsburgh School of Medicine | University of Bristol | Dartmouth College | University of Iowa | Gabrail Cancer Center Research | Cedars-Sinai | Children's Hospital Los Angeles | Nati","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Nationwide Children\u2019s Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nationwide Children\u2019s Hospital \/ National Institutes of Health | Abbott Laboratories | The University of Pittsburgh School of Medicine | University of Bristol | Dartmouth College | University of Iowa | Gabrail Cancer Center Research | Cedars-Sinai | Children's Hospital Los Angeles | Nati","highestDevelopmentStatusID":"1","companyTruncated":"Nationwide Children\u2019s Hospital \/ National Institutes of Health | Abbott Laboratories | The University of Pittsburgh School of Medicine | University of Bristol | Dartmouth College | University of Iowa | Gabrail Cancer Center Research | Cedars-Sinai | Children's Hospital Los Angeles | Nati"},{"orgOrder":0,"company":"Cagent Vascular LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Cagent Vascular LLC","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cagent Vascular LLC \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Cagent Vascular LLC \/ Undisclosed"},{"orgOrder":0,"company":"Alucent Biomedical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Alucent Biomedical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alucent Biomedical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Alucent Biomedical \/ Undisclosed"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Abbott Laboratories \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Abbott Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Inari Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Inari Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inari Medical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Inari Medical \/ Undisclosed"},{"orgOrder":0,"company":"Inari Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Inari Medical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inari Medical \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Inari Medical \/ Undisclosed"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Athena Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tris Pharma Inc \/ Athena Bioscience","highestDevelopmentStatusID":"1","companyTruncated":"Tris Pharma Inc \/ Athena Bioscience"},{"orgOrder":0,"company":"Organicell Regenerative Medicine","sponsor":"Beauty Health","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Organicell Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Organicell Regenerative Medicine \/ Beauty Health","highestDevelopmentStatusID":"1","companyTruncated":"Organicell Regenerative Medicine \/ Beauty Health"},{"orgOrder":0,"company":"Elastrin Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Elastrin Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elastrin Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Elastrin Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Azienda Ospedaliero-Universitaria Careggi","sponsor":"University of Florence | Northumbria University | Synbiotec Srl | University College Dublin | Fundaci\u00f3 d'investigaci\u00f3 Sanit\u00e0ria de les Illes Balears","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Azienda Ospedaliero-Universitaria Careggi","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azienda Ospedaliero-Universitaria Careggi \/ University of Florence | Northumbria University | Synbiotec Srl | University College Dublin | Fundaci\u00f3 d'investigaci\u00f3 Sanit\u00e0ria de les Illes Balears","highestDevelopmentStatusID":"1","companyTruncated":"Azienda Ospedaliero-Universitaria Careggi \/ University of Florence | Northumbria University | Synbiotec Srl | University College Dublin | Fundaci\u00f3 d'investigaci\u00f3 Sanit\u00e0ria de les Illes Balears"},{"orgOrder":0,"company":"Syntrillo, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Syntrillo, Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syntrillo, Inc \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Syntrillo, Inc \/ Undisclosed"}]

    Find Novel Drugs for Cardiology/Vascular Diseases under Development

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ekrem Bilal Karaayvaz

                            Country arrow
                            BioJapan
                            Not Confirmed

                            Ekrem Bilal Karaayvaz

                            Country arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ozone

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Sponsor : Medicana

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Ozone Treatment on CFR in Heart Failure Patients with Reduced EF

                            Details : Ozone is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Heart Failure, Systolic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 21, 2025

                            Lead Product(s) : Ozone

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Medicana

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Syntrillo, Inc

                            Country arrow
                            BioJapan
                            Not Confirmed

                            Syntrillo, Inc

                            Country arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Syntrillo Telehealth Stroke Risk Reduction Study

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Hypertension.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 15, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Azienda Ospedaliero-Universitaria Careggi

                            Country arrow
                            BioJapan
                            Not Confirmed

                            Azienda Ospedaliero-Universitaria Careggi

                            Country arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Sponsor : University of Florence | Northumbria University | Synbiotec Srl | University College Dublin | Fundació d'investigació Sanitària de les Illes Balears

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Functional Food Targeting Microbiota-Inflammation-Brain Axis to Prevent Undernutrition

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Atrial Fibrillation.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 22, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : University of Florence | Northumbria University | Synbiotec Srl | University College Dublin | Fundació d'investigació Sanitària de les Illes Balears

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Verve Medical

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Verve Medical

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Sponsor : RQM+ | Dabl Ltd | Medical Labs Memphis - MLM

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Renal Pelvic Denervation Pilot Trial

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Hypertension.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 04, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : RQM+ | Dabl Ltd | Medical Labs Memphis - MLM

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nicosia General Hospital

                            Country arrow
                            BioJapan
                            Not Confirmed

                            Nicosia General Hospital

                            Country arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ascorbic Acid

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Sponsor : University of Cyprus | AVVA Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Dietary Supplements on Quality of Care in CABG Patients

                            Details : Vitamin C is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Cardiovascular Diseases.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            May 29, 2025

                            Lead Product(s) : Ascorbic Acid

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : University of Cyprus | AVVA Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Centro de Edafología y Biología Aplicada del Segura

                            Country arrow
                            BioJapan
                            Not Confirmed

                            Centro de Edafología y Biología Aplicada del Segura

                            Country arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plant Based Extract Rich In Phytosterols, Phytostanols, Resveratrol & Hydroxytyrosol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Sponsor : Universidad Católica San Antonio de Murcia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Functionality of an Extract Rich in Phytosterols and Phytostanols on Parameters Related to t...

                            Details : Plant Based Extract Rich In Phytosterols, Phytostanols, Resveratrol & Hydroxytyrosol is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Hypercholesterolemia.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            May 01, 2025

                            Lead Product(s) : Plant Based Extract Rich In Phytosterols, Phytostanols, Resveratrol & Hydroxytyrosol

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Universidad Católica San Antonio de Murcia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Scilex Pharmaceuticals

                            U.S.A arrow
                            BioJapan
                            Not Confirmed

                            Scilex Pharmaceuticals

                            U.S.A arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Scilex Wins FDA Orphan Drug Status for Colchicine in Pericarditis

                            Details : Gloperba (colchicine) disrupts the polymerization of β-tubulin into microtubules, thereby preventing the activation, degranulation & migration of neutrophils to sites of inflammation in pericarditis.

                            Product Name : Gloperba

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            April 16, 2025

                            Lead Product(s) : Colchicine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Beijing Anzhen Hospital

                            Country arrow
                            BioJapan
                            Not Confirmed

                            Beijing Anzhen Hospital

                            Country arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Sponsor : Abbott Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Catheter abLation in patiEnts With seVere Atrial Functional Mitral regurgiTation and pE...

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Atrial Fibrillation.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 19, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Abbott Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            IBSA Institut Biochimique

                            Switzerland arrow
                            BioJapan
                            Not Confirmed

                            IBSA Institut Biochimique

                            Switzerland arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Sponsor : Informapro Srl

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Effects of Two Dietary Supplement Formulations on the Lipid Profile in Mild Hypercholesterol...

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Hypercholesterolemia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 05, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Informapro Srl

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Nova Scotia Health Authority

                            Canada arrow
                            BioJapan
                            Not Confirmed

                            Nova Scotia Health Authority

                            Canada arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Protein

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Sponsor : Dalhousie University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Investigating the Combined Effects of Protein, Blueberries, and Exercise on Cardiovascular Health and Frailty ...

                            Details : This is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Cardiovascular Diseases.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            November 18, 2024

                            Lead Product(s) : Protein

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Dalhousie University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth